Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer.

Enfortumab vedotin (EV) and sacituzumab govitecan (SG) are antibody-drug conjugates (ADCs) approved for treatment of advanced bladder cancer and are being investigated in earlier disease states. Radiation is a component of bladder-sparing trimodal therapy, a curative treatment approach for muscle-invasive bladder cancer (MIBC). In this study we assessed the impact of radiation on ADC target expression and investigated the activity and toxicity of combining radiation with ADCs in preclinical models of bladder cancer.

European urology. 2024 Mar 23 [Epub]

Yuzhen Zhou, Vincent D D'Andrea, Surish P Shanmugam, Isabella Stelter, Dag R Stormoen, Rea Chroneos, Timothy Hanlon, Ilana Epstein, Raie T Bekele, William J Anderson, Filipe F L Carvalho, Joaquim Bellmunt, Kent W Mouw

Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

, Department of Urology, Brigham & Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Harvard Medical School, Boston, MA, USA; Department of Pathology, Brigham & Women's Hospital, Boston, MA, USA., Department of Urology, Brigham & Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Harvard Medical School, Boston, MA, USA; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Radiation Oncology, Brigham & Women's Hospital, Boston, MA, USA. Electronic address: .

Go Beyond the Abstract and Read a Commentary by the Authors